


Bumetanide to treat brain disorders: when the empire strikes back!

The first 1000 days, based on the work of Yehezkel Ben-Ari

Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents

The challenges of in-vivo GABA and glutamate measurements in the preterm neonatal brain

Cesarean Section delivery in mice leads to smaller brain volumes at birth

There is not a single Autism-specific gene, just brain genes !

Use of machine learning to identify at birth babies at risk of developing Autism Spectrum Disorders

The Complex effects of Anti-Epileptic Drugs and Neonatal Seizures
